USA-based specialty pharmaceutical company Zynerba Pharmaceuticals, focused on innovative transdermal cannabinoid treatments, has named two leading industry veterans to lead the company.
Armando Anido (pictured left) will serve as chairman of the board and chief executive officer, and Terri Sebree will serve as president. Mr Anido and Ms Sebree will lead the first and only transdermal cannabinoid therapeutic company as it prepares to initiate Phase I clinical studies in 2015 on ZYN001, a proprietary prodrug of THC transdermal patch, and ZYN002, a proprietary cannabidiol (CBD) transdermal gel.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze